Moderna, Inc. (MRNA)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Product Sales Revenue	2.08B	1.82B	3.11B
Product Sales Revenue Growth	14.63%	-41.52%	-53.40%
Grant Revenue	-	22.00M	37.00M
Grant Revenue Growth	-	-40.54%	-60.64%
Collaboration Revenue	17.00M	13.00M	48.00M
Collaboration Revenue Growth	30.77%	-72.92%	-42.17%
Licensing and Royalty Revenue	-	11.00M	42.00M
Licensing and Royalty Revenue Growth	-	-73.81%	-
Stand-Ready Manufacturing Revenue	100.00M	80.00M	-
Stand-Ready Manufacturing Revenue Growth	25.00%	-	-
Revenue (Other)	24.00M	-	-
Revenue (Total)	2.23B	1.94B	3.24B
Revenue (Total) Growth	14.46%	-39.93%	-52.74%

Data Source: Fiscal.ai Last updated: May 1, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 26, 2026

Data Sources Report a data error